The medicine
Semaglutide is a man-made version of a hormone released by the gut after eating. Ozempic, Wegovy, and Rybelsus are product names for this ingredient.
Semaglutide is a man-made version of a hormone released after eating. It helps signal fullness and helps the body handle sugar.
The medicine stays in the body for a long time. That is one reason the person who writes the prescription needs to know about other medicines, health conditions, and pregnancy plans.
As of September 2026, Ozempic was approved for adults with type 2 diabetes. Its label said it could lower heart attack and stroke risk for some of those adults and slow kidney disease for some with long-term kidney problems.
Ozempic was not approved for weight loss.
As of September 2026, Wegovy was the semaglutide brand approved for weight management.
Its injection label also covered some teens, certain people with heart disease, and some adults with a serious fatty liver condition.
As of September 2026, Ozempic and Wegovy both had tablet forms as well as injections.
Rybelsus was the older diabetes tablet name. The FDA record said those tablets were being replaced, but it gave no end date.
On a box, bottle, prescription, or product page, look for “active ingredient: semaglutide.” That does not tell you the brand, form, approved use, or who made the product.
Ask for those details separately.
The STEP 1 trial studied adults with excess weight who did not have diabetes. Both groups also received lifestyle support.
Trial averages do not predict one person’s result. Both groups had regular study visits and help with eating and activity, and the drug maker funded the study. Ask an online service how often it provides visits and what support they include.
A follow-up study watched 327 people from the STEP 1 trial after treatment stopped and found that during the next year they regained about two-thirds of their earlier weight loss.
That result does not settle how long one person stays on treatment. It shows why the long-term plan belongs in the first conversation.
A generic is an approved copy reviewed by the FDA. Medicine made to order for one patient is called compounded medicine. As of September 2026, compounded medicine was not FDA-approved.
As of September 2026, no generic semaglutide could be marketed in the United States. Apotex had tentative approval, meaning the FDA found its application acceptable but the product could not be sold yet.
As of September 2026, a product described as “generic Ozempic” was not an approved generic.
A clear answer names the product, form, maker, and pharmacy. If it is made to order, the answer also states the medical reason for that patient, such as an allergy to a dye in an approved product.
A vague answer such as “medical semaglutide” leaves the important part out.
Read the caution page